[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vivosim Lab Inc (VIVS)

Vivosim Lab Inc (VIVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,808
  • Shares Outstanding, K 2,608
  • Annual Sales, $ 140 K
  • Annual Income, $ -2,480 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 1.43
  • Price/Sales 24.34
  • Price/Cash Flow N/A
  • Price/Book 0.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2500 +18.40%
on 04/01/26
1.8900 -21.69%
on 04/17/26
-0.2000 (-11.90%)
since 03/20/26
3-Month
1.2500 +18.40%
on 04/01/26
3.4000 -56.47%
on 01/30/26
-0.5200 (-26.00%)
since 01/22/26
52-Week
1.2500 +18.40%
on 04/01/26
5.3000 -72.08%
on 09/15/25
-0.5300 (-26.37%)
since 04/22/25

Most Recent Stories

More News
VivoSim Announces Pricing of up to a $4 Million Public Offering

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical...

VIVS : 1.4800 (+1.35%)
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 1.4800 (+1.35%)
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 1.4800 (+1.35%)
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 1.4800 (+1.35%)
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical...

VIVS : 1.4800 (+1.35%)
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing...

VIVS : 1.4800 (+1.35%)
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing...

VIVS : 1.4800 (+1.35%)
VivoSim: Fiscal Q1 Earnings Snapshot

VivoSim: Fiscal Q1 Earnings Snapshot

VIVS : 1.4800 (+1.35%)
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

VIVS : 1.4800 (+1.35%)
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

VIVS : 1.4800 (+1.35%)

Business Summary

VivoSim Labs Inc. is a clinical-stage biotechnology company. It involved in developing drugs which are demonstrated to be effective in three-dimensional human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease. VivoSim...

See More

Key Turning Points

3rd Resistance Point 1.6800
2nd Resistance Point 1.6200
1st Resistance Point 1.5500
Last Price 1.4800
1st Support Level 1.4200
2nd Support Level 1.3600
3rd Support Level 1.2900

See More

52-Week High 5.3000
Fibonacci 61.8% 3.7529
Fibonacci 50% 3.2750
Fibonacci 38.2% 2.7971
Last Price 1.4800
52-Week Low 1.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.